Differential assessment of αSMA expression intensity for CAFs (performed by DIA to obtain stromal score like has been described in the present study) may suggest CAFs’ heterogeneity from BC stroma and may recommend additional tests to predict poor prognosis and/or recurrence by pathologists. The gene discussed is ACTA1; the disease is breast cancer.